




Con

SCHILDE





CHOOSE TRANSFORMATION

IRIDICA -A NEW KIND OF CERTAINTY

Klimud 2015 / Belek - Antalya

Dr. Jessica Schilde Molecular Application Specialist, EMEA



IRIDICA – A new kind of certainty

Complete SOLUTION

- An end-to-end solution from specimen to answer
- Sample ID tracking throughout the process
- Automated, simple results reporting

Comprehensive COVERAGE

- Unprecedented Coverage (bacteria, fungi, and viruses)
- 1,000 pathogens

Short TURN AROUND TIME

< 6 HOUR Time to First Result

Direct <u>SAMPLES</u>, different <u>SAMPLE TYPES</u>

- Direct Sample Testing, culture not required.
- Whole blood; Sterile fluids and tissues; BAL, ETA; Plasma

Reliable IDENTIFICATION

- Identifies one or more pathogens in poly-microbial infections
- Not affected by antimicrobial pre-treatment

CHOOSE TRANSFORMATION






THE IRIDICA TECHNOLOGY

CHOOSE TRANSFORMATION



PCR/ESI-MS Technology


 The IRIDICA technology combines two Nobel-prize winning technologies: PCR and ESI/MS



CHOOSE TRANSFORMATION









Workstation Home Screen


	Home	SIGNED IN support	Sign O	ut 4:06 PM Friday, March 20, 2015	iridica.				
Alert Center	SYSTEM STATUS Analysis Server 🤡 Device Ser	rvice 🤡							
Home Status	Bead Beater 1 Ready	Sample Prep 1 Ready							
Bead Beater Sample Prep			San	nple Prep		SIGNED castrsa	Sig	n Out 12:31 PM Monday, October 27, 2	014 Iridica.
Sample Prep Thermal (Viral) Cycler		Alert Center		e Input					
			. *	Test Order 33454	Bead Beating Tube	Process Tube	Elution Tube	Reagent Cartridge	Assay Strip
		Home Sample Status	1	IRIDICA Fungal Assay IVD (BFNG51) 44522	Lot: 707311 ID: 116253	0000116251	0000116251	Exp: 2024-10-06 ID: 116252 Lot: 707311	
Desalter Mass Spec			3	IRIDICA BAC LRT Assay IVD (PNEU71) 33454 IRIDICA BAC LRT Assay IVD (PNEU71)	ID: 693369	0000116253	0000116253	Exp: 2024-10-06 ID: 116253 Lot: 707311 Exp: 2024-10-06	
		Bead Beater Sample Pre	4						
Message IRIDICA History Browser			5						
History Browser		Sample Prep Sample Prep Desalter Desalter Mass Spec	6 Reset f	form Delete Row Sel	1 2 3 4	5 6 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2 3 4 5 6	vice Lab Items	

Sample Prep Loading Screen


CHOOSE TRANSFORMATION








Pre-Amplification Workflow Nucleic Acid Extraction and Assay Strip Setup






CHOOSE TRANSFORMATION

Post-Amplification Workflow *Amplification, Desalting and Analysis*



Organism Identification




CHOOSE TRANSFORMATION

Company Confidential ©2014 Abbott

Abbott

Broad Amplification


Primers are designed in a way that they span two universally conserved regions not too far apart from each other, but where the nucleotides in between the conserved regions are variable and differ with each unique species.



CHOOSE TRANSFORMATION




Broad Amplification





CHOOSE TRANSFORMATION

Mass Spectrometry of PCR Amplicons, Signal Processing and Organism Identification by Triangulation





CHOOSE TRANSFORMATION

Iridica.	Summa Sample ID: test_4neg	ARY REPORT		
Entry Date: 23 Spray Date: 23 Result Date: 23 Mass Spec ID: Ma	gative Control -Oct-2014 8:29 AM -Oct-2014 5:48 PM -Oct-2014 5:57 PM assSpec 1 (MS01) salter 1 (DS01)		0.10349 0.42	IRIDICA Run Detail information
WARNING: Negative	Control sample has detections.	Flags		Assay Flags or Alerts
Detected Organism Staphylococcus aure Detected Organism Not Detected	us	acteria Fungi	Q Score Level 0.96 2 Q Score Level 	Bacteria and Fungi Detection sections
Detected Marker KPC mecA vanA vanB	Result n/a Not Detected n/a n/a	larker	Q Score Level 	Drug Resistance Marker section
Detection Extraction Control	C	ontrol	Q Score Level 0.97 187	Extraction Control Detection section

CHOOSE TRANSFORMATION

Abbott

Broad Assay Menu and Sample Types


IRIDICA ASSAY	Assay Type	Coverage	Selected Diseases/Patient groups
BAC BSI1BAC SFT2	<u>B</u> lood <u>s</u> tream <u>i</u> nfection <u>S</u> terile <u>f</u> luids and <u>t</u> issues	780 Bacteria and <i>Candida</i> , 4 Antibiotic Resistance Markers: <i>mecA</i> , <i>vanA</i> , <i>vanB</i> and <i>kpc</i>	Sepsis Joint prosthetics infection
BAC LRT 3	<u>L</u> ower <u>r</u> espiratory <u>t</u> ract	Identical coverage with semi-quantitative threshold	Pneumonia, IC patients
Fungal	Fungal	> 200 fungi and yeast	Pneumonia, IC Patients
Viral IC 5	Viral- <u>I</u> mmuno <u>c</u> ompromised	13 viral reporting groups covering > 130 viral species	IC Patients

CHOOSE TRANSFORMATION

Company Confidential ©2014 Abbott

Abbott


Parallel processing of different Assays & Samples



CHOOSE TRANSFORMATION



IRIDICA Hands-on & Walk-away Times





Company Confidential ©2014 Abbott

CHOOSE TRANSFORMATION



STUDIES & PUBLICATIONS

CHOOSE TRANSFORMATION



The RADICAL Study

Rapid Diagnosis of Infection in the Critically II, a Multicenter Study of Molecular Detection in Bloodstream Infections, Pneumonia, and Sterile Site Infections*

Jean-Louis Vincent, MD, PhD, FCCM¹; David Brealey, MD²; Nicolas Libert, MD³; Nour Elhouda Abidi, MD⁴; Michael O'Dwyer, MD⁵; Kai Zacharowski, MD⁶; Malgorzata Mikaszewska-Sokolewicz, MD⁷; Jacques Schrenzel, MD⁸; François Simon, MD⁹; Mark Wilks, PhD⁵; Marcus Picard-Maureau, PhD¹⁰; Donald B. Chalfin, MD, MPH¹¹; David J. Ecker, PhD¹¹; Rangarajan Sampath, PhD¹¹; Mervyn Singer, MD²; the Rapid Diagnosis of Infections in the Critically Ill Team

Critical Care Medicine, 2015 Nov;43(11):2283-91


- A Multicenter Observational Trial to Evaluate the Potential Clinical Impact of IRIDICA
- Nine ICUs in six European countries as study sites
- Analysis of 616 bloodstream infection,185 pneumonia and 110 sterile fluid and tissue specimens from 529 patients



The RADICAL Study Key Findings

Performance against culture in RADICAL:

- Sensitivity: >81%
- NPV: 97% for blood stream infections
- 3X greater recovery of pathogens



CHOOSE TRANSFORMATION


Abbott

IRIDICA Early Assessment Program

INDICA

Comparison of the new PCR/ESI-MS platform IRIDICA with quantitative culture for detection of bacterial pathogens in bronchoalveolar lavage fluids of patients with suspected pneumonia Philip Kirschner¹, Sabrina Woltemate¹, Ines Yang¹, Stefan Ziesing¹, Tobias Welte², Sebastian Suerbaum¹ Merchannen Metricken and Bestein Enternistic and Descenting of Discontinue of Princeson Medical School Carl-Neuben-Str 1 3005 Hat iology and ²Dep

al Microbiology and H Introduction Abbott PCRESI MS (IRDICA) assay (Fg. 1) is a qualitative in vito text for the detection i detrification of bacterial and Candda nucleic acids through PCR amplification and sequent electro-gray ionization mass spectremely analysis. The test can abis object the sence of genes encoding restatance to certain antibiotics (meoR, vanR, vanR, and KPC) in ocation with spectro. backetial detectors. association with specific loaderial detection: The and of the shuty with specific loaderial detection: The and of the shuty with specific loaderial detection in the specifi



Evaluation of the Broad-Range PCR/ESI-MS

Dr. Mark Wilks Claim Scientist Mere Elena Jordana-Lluch^{1,2,£} Clara Marcó¹, M^a Jesús I benefit from the PCR/ESI-MS technology? There are a number of distinct clinical groups for which this technology promises to be Vicente Ausina^{1,2,5}

Infections

CLINICAL BENEFITS OF RAPID PATHOGEN TESTING WITH PCR/ESI-MS

M POINT-OF-VIEW

Barts Health NHS Tract in London, UK, talks about their experiences of using PCR/ESI-MS technology ever a period of 18 months. During its use for the RADICAL study, the Which patient groups could potentially

> quite rewarding, including patients with severe sepsis, pneumonia and compromised immune systems. Patients can be immuno-compromised because they have recently had

compromised because they have recently had a transplant, or they could be havematology oncology or HIV patients. All the immuno-compromised groups tend to be infected with musual bacteria and fungi, which you might not normally look for. In addition ordinary

bacteria, which do not harm immunocom petent people, can have serious consequences in this group.

How would you summarise your experi-ence with this technology? In general it's been quite an exciting process and one which has caused a lot of interest in

microbiology and in different clinical depar

nents in the hospital. In some cases it has

ments in the bospital. In some cases it has been quite difficult to interpret the results, because there has been no technology like this before, so we have no framework with which to base our understanding of the

results. It is a steep learning curve. Occasion-ally we have been baffled by an unexpected nism, one that is quite hard to culture in the laboratory usually

How noise that exceeding infer to conven-tional testing and what are in a dwatarese.¹ We this technology you do not need to try There are a number of ways in which it differs from conventional microbiology testing. First from conventional microbiology testing first is the speed of testing. We are used to a kind of "gardening' approach, where nothing much does the thinking for you. You just look for any happens for a minimum of 18 hours or perhaps infectious agent. 2 or 3, whereas with PCR/ESI-MS technology

results are available in 6 hours. Another differ- How would you recence is that a lot of bacteria and copecially fungi are very difficult to grow and are very slow growing So with PCR/ESI-MS technology we and composite the sample through

Direct detection of Mycobacterium tuberculosis

I year old boy with possible septic arthritis in one elbow, but all testing for bacteria and viruse) year all by weak possible steps arbitration one of these bund a locating for theorem at the steps of the step of

34-pass of at much trailer, PMI of prephorms. Admitted segrec, mentingtic (Brut CL scan brain brain brain the segrec structure) and the segrect segment of the segrect segment of the segrect segment of the segrect segment brain segment of the segrect segment of the segrect segment of the segrect segment of the segrect segment segment

ICU Management 3 - 2015

and y mag at parties much fins all registry in the devision of the possibility of alloctions in the possibility of alloctions alloction in the possibility of alloction alloction in the possibility of alloction allocation in the possibility of alloctions allocations al

M POINT-OF-VIEW

dence in the results to rule out infection. For tion. However, the consequences of not treating example, a lot of patients in ICU, who were an invasive fungal infection are so serious that example, a tox or parente in itco, ware were an instance impairmention are to serious that thought to be septic, scientify don't have any the update are not take the risk. This implications infection at all. They might have SIRS, but that could be nothing to do with infection... is could be to surgery, trauma or anodher reason. Trust, for example, spends up to two million

Ifidica, identify early . treat with confidence . transform care

and you get a positive result then it's up to you But obviously the possibility of infection has pounds per year on antifungal tr on that read and therefore to top trends and analysis to polymeric of the three spents. The set of the set of

DISCLOSURE: "Point-of-View" articles are part of the ICU Management Corporate Engagement Program



To learn more about IRIDICA, please visit http://iridica.abbott.cor CHOOSE TRANSFORMATION™

IRIDICA - ENABLING EARLIER TRANSITION TO OPTIMIZED ANTIMICROBIAL THERAPY.

OVER 1,000 PATHOGENS . 6 HOURS . DIRE CLINICAL SAMPLES



CHOOSE TRANSFORMATION

Thank you!

CHOOSE TRANSFORMATION

